Molecular Vision 2013; 19:1723-1733 <>
Received 14 September 2012 | Accepted 31 July 2013 | Published 04 August 2013

LDLR–/–ApoB100/100 mice with insulin-like growth factor II overexpression reveal a novel form of retinopathy with photoreceptor atrophy and altered morphology of the retina

Kati Kinnunen,1,2 Suvi E. Heinonen,1 Giedrius Kalesnykas,1,2 Svetlana Laidinen,1 Hannele Uusitalo-Järvinen,3 Hannu Uusitalo,3 Seppo Ylä-Herttuala1,4,5

The first two authors with equal contribution

1Department of Biotechnology and Molecular Medicine, A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland; 2Department of Ophthalmology, University of Eastern Finland, Kuopio, Finland; 3Department of Ophthalmology, Tampere University Hospital, Tampere, Finland; 4Gene Therapy Unit, Kuopio University Hospital, Kuopio, Finland; 5Research Unit, Kuopio University Hospital, Kuopio, Finland

Correspondence to: Seppo Ylä-Herttuala, Department of Biotechnology and Molecular Medicine, A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, P.O. Box 1627, FI-70211 Kuopio, Finland; Phone: +358 17 163 075; FAX: + 358 17 163 751; email:


Purpose: The aim of this study was to characterize the ocular morphology of low-density lipoprotein receptor–deficient apolipoprotein B-100-only mice, where overexpression of insulin-like growth factor II (IGF-II) has been shown to induce glucose intolerance and increase atherosclerotic lesion progression and calcification.

Methods: Fifteen-month-old mice were examined on a normal chow diet and after 3 months of a high-fat Western diet. IGF-II-negative LDLR–/–ApoB100/100 littermates and C57Bl/6J mice served as controls. In vivo color images of the fundi were obtained, and eyes were processed either for retinal flat mounts for assessment of neovascularization or for paraffin-embedded samples for immunohistochemical analyses.

Results: IGF-II overexpression and the resulting prediabetic phenotype did not induce microvascular damage when assessed in fundus photographs and retinal whole mounts, and the number of capillaries in IGF-II/LDLR–/–ApoB100/100 mice was not significantly different from LDLR–/–ApoB100/100 mice. However, morphology of the inner nuclear, outer plexiform, and outer nuclear layers was altered in the IGF-II/LDLR–/–ApoB100/100 mice. Moreover, photoreceptor atrophy and thinning of the outer nuclear layer were present. Caspase-3 staining was positive in the photoreceptor inner segment. In addition, retinas of the IGF-II/LDLR–/–ApoB100/100 mice displayed reduced rhodopsin positivity, consistent with the decreased number of photoreceptor cells.

Conclusions: This study reports a novel form of retinopathy with photoreceptor atrophy and abundant changes in retinal morphology in a mouse model of prediabetes and atherosclerosis.


Type 2 diabetes (T2D) is associated with multiple metabolic abnormalities promoting vascular complications—elevated blood glucose, insulin resistance, and atherogenic lipid abnormalities. This high prevalence of concomitant cardiovascular risk factors contributes to accelerated atherosclerosis and dysfunction of both small and large arteries. As a result, atherosclerotic macrovascular disease processes are more aggressive and diffuse in diabetic patients. Since many of these metabolic perturbations are present well before overt hyperglycemia, processes contributing to vascular complications can be initiated 5–10 years before the development of full-blown diabetes [1].

In addition to macrovascular diseases, which are the major cause of death in diabetes, microvascular complications underlie significant morbidity and premature mortality in diabetic patients. Diabetic retinopathy (DR) is the most common microvascular complication and the leading cause of blindness in the working population in the Western world [2]. The pathogenesis of DR is complex, consisting of both biochemical and histological alterations that lead to damage in retinal vasculature and neural cells. Although it is well known that hyperglycemia is a major risk factor for DR, there is no glycemic threshold for the development of these long-term complications [3]. Therefore, in 25% of T2D patients these changes can be asymptomatically present at the time of diabetes diagnosis [4]. In addition, while generally associated with macrovascular complications, dyslipidemia has been shown to correlate with the status of DR; increased levels of triglycerides and low-density lipoproteins (LDL) in plasma as well as a concentration of LDL particles and apolipoprotein B (ApoB) in the retinal hard exudates have been associated with the severity of retinopathy [5,6].

Metabolic disorders often associated with T2D predispose the individual to other eye diseases. Age-related macular degeneration (AMD), the leading cause of irreversible blindness among older people [7], is initiated with the accumulation of lipid-rich deposits under the RPE and within Bruch’s membrane [8,9]. Epidemiologic studies have suggested that dietary fat and cholesterol play an important role in the pathogenesis of AMD [10]. The role of LDL cholesterol in the pathogenesis of AMD is also seen in LDL receptor knockout (LDLR–/–) mice, which exhibit abnormalities in Bruch’s membrane characterized by thickening and deposition of lipid-rich particles [11] similar to the drusen seen in patients with AMD [12]. ApoB is also known to be present in RPE and Bruch’s membrane under normal conditions and in drusen and basal deposits of AMD patients [13]. Similarly, transgenic mice expressing human ApoB develop basal laminar deposits in Bruch’s membrane after a high-fat diet [14]. Moreover, when made hypercholesterolemic in the LDLR–/– background, these human ApoB transgenic LDLR–/– mice have been found to accumulate esterified cholesterol at the basement of the RPE and develop alterations seen in electroretinography, indicating photoreceptor dysfunction [15].

We previously generated a novel mouse model of the prediabetic features and atherosclerosis by overexpressing insulin-like growth factor II (IGF-II) in an atherogenic LDLR–/–ApoB100/100 background and characterized the macrovascular phenotype [16,17]. We found that in old animals, disturbances in glucose metabolism increase lesion progression and calcification without changes in plasma lipid levels compared to only hypercholesterolemic LDLR–/–ApoB100/100 controls. In this study, we characterized the ocular morphology of the IGF-II/LDLR–/–ApoB100/100 mouse model.



IGF-II/LDLR–/–ApoB100/100 mice represent a model of diabetic macroangiopathy and have been previously described [16]. In brief, mice deficient of LDL receptor and expressing only apolipoprotein B100 (LDLR–/–ApoB100/100) [18] in a C57BL/6×129/SvJae background (The Jackson Laboratory, Bar Harbor, ME) were crossbred with C57BL6/SJL mice overexpressing IGF-II in pancreatic β-cells [19]. IGF-II-negative LDLR–/–ApoB100/100 littermates served as controls. Both sexes were included in the study groups. In principle, 15-month-old mice that had either been fed ad libitum a normal chow diet (R36; Lactamin, Kimsta, Sweden, n=6/strain) or fed a high-fat Western diet for 12–15 months (TD 88,173, Harlan Teklad, Madison, WI, 42% of calories from fat and 0.15% from cholesterol, no sodium cholate, n=9–12/strain) were examined. We also included 15-month-old C57Bl/6J mice on a Western diet (n=9) in histological analyses. During experiments mice were anesthetized using xylazine (10 mg/kg) and ketamine (80 mg/kg) subcutaneously and euthanized using carbon dioxide. Mice were housed in groups and maintained in a temperature- and humidity-controlled environment with a 12-h light–dark cycle at the National Laboratory Animal Centre in Kuopio. All protocols involving the use of mice adhered to the regulations set forth in the Association for Research in Vision and Ophthalmology (ARVO) Statement for the Use of Animals in Ophthalmic and Vision Research and were approved by the Experimental Animal Committee of the University of Kuopio.

Metabolic analyses

Blood glucose was determined using a Glucometer Elite analyzer (Bayer, Elkhart, IN). Plasma insulin levels were measured using an ELISA kit (Rat/mouse Insulin ELISA Kit; Linco Research Inc., St. Charles, MO). From overnight fasted plasma samples, triglycerides (Ecoline® S+, Diasys, Diagnostic Systems Gmbh, Holzheim, Germany) and total cholesterol (Ecoline® 25, Merck KgaA, Darmstadt, Germany) were measured as described previously [20].

Fundus photography

In vivo color images of the fundi were obtained by fundus camera (Nikon D70s; Nikon Corp., Tokyo, Japan). Photographs were also taken from the anterior segments. In addition, the eyes were evaluated by a slit lamp and ophthalmoscopy. The fundi were photographed after dilation of the pupils with one drop of tropicamide (5 mg/ml) and phenylephrine hydrochloride (100 mg/ml; Kuopio University Hospital, Kuopio, Finland).

Retinal whole mounts

Mice were euthanized and the eyes enucleated. After a 10-min fixation in 4% paraformaldehyde (PFA), the cornea, lens, sclera, and vitreous were excised and the retina isolated. Retina flat mounts (from four to five 15-month-old animals/group on a Western diet) were fixed with 4% PFA for 1 h and stained for capillaries with fluorescence-conjugated isolectin Griffonia simplicifolia (1:150, GS lectin, I-21413; Molecular Probes, Eugene, OR). For immunohistochemistry, retinas were blocked in 20% fetal bovine and 20% normal goat serum and stained for pericytes with anti-chondroitin sulfate proteoglycan antibody, a cell-surface proteoglycan marker (1:200, Chemicon, Billerica, MA), followed by appropriate fluorescence-conjugated secondary antibodies. Whole mount retinas were imaged using confocal microscopy (Olympus IX70, Perkin Elmer, Waltham, MA) with a 4×objective lens. Overlapping images were assembled into whole retina montages using Photoshop 6.0 (Adobe, San Jose, CA). Areas of vascular obliteration and neovascular tufts were quantified from these montages.

Histological evaluation of paraffin-embedded retinal sections

Mice were sacrificed and perfused with PBS (137 mM sodium chloride, 10 mM phosphate, 2.7 mM potassium chloride) and 4% PFA, pH 7.4. Immunohistochemical stainings were performed on serial 6-μm sections. Morphological alterations were analyzed with hematoxylin and eosin (H&E)-stained radial sections. Samples were immunostained with antibodies against IGF-II (1:100; GroPep Limited, Thebarton, Australia), macrophages (mMQ AIA31240, 1:5,000; Accurate Chemical & Scientific Corp., Westbury, NY), CD31 (platelet endothelial cell adhesion molecule [PECAM]- 1,1:50; BD Biosciences PharMingen, San Diego, CA), caspase-3 (1:250, Promega Corp., Fitchburg, WI), receptor for advanced glycation end products (RAGE, 1:50; R&D Systems, Minneapolis, MN), interleukin 6 (IL-6, 1:300; Lifespan Biosciences, Seattle, WA), intercellular adhesion molecule 1 (ICAM-1, 1:500; R&D Systems, Minneapolis, MN and vascular cell adhesion molecule 1 (VCAM- 1), 1:100; Chemicon), caspase-1 (1:100; Imgenex, Odisha, India), calbindin (1:1,000; SWANT, Bellinoza, Switzerland), calretinin (1:1,000; SWANT), rhodopsin (1:500, Chemicon), and heat shock proteins 25 kDa (HSP-25, 1:500), 60 kDa (HSP-60, 1:500), and 70 kDa (HSP-70,1:200; all from Stressgenbioreagents, Kampenhout, Belgium). Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL; Apop Tag plus peroxidase in situ apoptosis detection kit; Millipore, Billerica, MA) was used to demonstrate apoptosic cells in the retina. Avidin-biotin–horseradish peroxidase system with 3,3′-Diaminobenzidine (DAB) was used for immunostainings. Photographs of the histological sections were taken using an Olympus AX70 microscope (Olympus Optical, Tokyo, Japan) and analyzed using analysis software (Soft Imaging System Gmbh, Lakewood, CO).

The number of cells in the inner (INL) and outer nuclear layers (ONL) and ganglion cell layer (GCL) was analyzed from H&E stained sections from the posterior pole near the optic nerve head in five animals per group and expressed as a percentage compared to that in the C57Bl/6J control group. Capillary density (capillaries/mm2) and mean capillary area (mm2) in the retina were calculated from CD31-immunostained sections. Quantification was performed from three sections per mouse, and three fields at 400× magnification were randomly selected in each section and analyzed with analySIS software (Soft Imaging System Gmbh).

Statistical analyses

An independent samples t test was used for metabolic analyses to evaluate statistical significance. One-way ANOVA with Bonferroni’s post test was used when analyzing cell counts in retinal layers. Numerical values for each measurement are shown as mean±standard deviation or mean±standard error of the mean. All statistical analyses were performed using GraphPad Prism version 4.0 (GraphPad Software, San Diego, CA).


Metabolic parameters

Metabolic parameters for the 15-month-old animals are presented in Table 1. On a Western diet, the IGF-II/LDLR–/–ApoB100/100 mice showed increased fasting glucose levels compared to the LDLR–/–ApoB100/100 controls (6.0±2.1 versus 3.8±1.6 mmol/l, p<0.05). No significant differences between the groups in bodyweights were detected for either the normal or Western diet. Profound hypercholesterolemia developed with the Western diet both in IGF-II/LDLR–/–ApoB100/100 and LDLR–/–ApoB100/100 control mice without any differences between the groups. No changes were present in fasting triglycerides.

In vivo examination of the eyes

In vivo examination of the eyes by biomicroscopy revealed no significant changes in either diabetic IGF-II/LDLR–/–ApoB100/100 mice fed with a normal or Western diet or in control animals. The pupils dilated normally with mydriatics indicating normal anatomy and physiology of the anterior parts of the eye. Signs of hyperpermeability of the vessels in the retinal layers, such as hemorrhages, edema, or exudates, were not observed. Retinal photographs revealed no clinically relevant changes in the retinas either in the IGF-II/LDLR–/–ApoB100/100 or control mice (data not shown).

Diabetes did not induce vascular changes in the retina

Diabetes in the IGF-II/LDLR–/–ApoB100/100 mice did not induce retinal neovessel formation on normal chow (Figure 1) or a Western diet (data not shown). No early microvascular diabetic changes, such as micro-aneurysms, hemorrhages, intraretinal microvascular abnormalities or lipid exudates were found in the retinas of IGF-II/LDLR–/–ApoB100/100 or control mice.

Histopathological changes and retinal degeneration in diabetic mice

In H&E-stained paraffin sections, altered retinal morphology was observed in 
IGF-II/LDLR–/–ApoB100/100 mice. Changes were present in all (six of six) old mice on a normal diet and in six of nine (67%) mice on a Western diet. There were displaced cells in the inner plexiform layer (IPL), and the morphology of the INL, outer plexiform layer (OPL), and ONL was abundantly altered. Photoreceptor atrophy was also observed in the IGF-II/LDLR–/–ApoB100/100 mice (Figure 2).The LDLR–/–ApoB100/100 mice presented normal retinal morphology similar to C57Bl/6J controls.

Cellularity in the ONL of IGF-II/LDLR–/–ApoB100/100 mice on a normal diet was decreased compared to both LDLR–/–ApoB100/100 mice (p<0.01) and C57Bl/6J controls (p<0.01; Figure 3). In addition, apoptotic cells indicated by TUNEL staining were present in the ONL in 63% of IGF-II/LDLR–/–ApoB100/100 mice, while no positivity was seen in LDLR–/–ApoB100/100 or C57Bl/6J mice (Figure 4).The number of cells in the INL in both IGF-II/LDLR–/–ApoB100/100 mice and LDLR–/–ApoB100/100 mice was decreased compared to C57Bl/6J controls (Figure 3), but the difference was statistically significant only in IGF-II/LDLR–/–ApoB100/100 mice (p<0.05). There were no statistically significant differences in the number of cells in the GCL between the groups, but a trend toward a reduced cell count was seen in IGF-II/LDLR–/–ApoB100/100 mice.

In immunohistochemical analyses, IGF-II was found to be expressed in the capillaries of the IGF-II/LDLR–/–ApoB100/100 mice but not in the control mice (Figure 5). However, the number of capillaries in the IGF-II/LDLR–/–ApoB100/100 mice was not increased compared to control mice (data not shown). Capillaries were similarly situated in the nerve fiber layer and in the OPL. Displaced cells in the IPL stained positively with calbindin and calretinin, which are specific markers for amacrine cells. There were no differences between the control and diabetic mice in retinal expression of HSPs. Moreover, the retinal expression of RAGE, caspase-1, IL-6, and adhesion molecules ICAM-1 and VCAM-1 were similar between the groups (data not shown). However, caspase-3 was abundantly positive in the inner segment of the photoreceptor cells in IGF-II/LDLR–/–ApoB100/100 mice (Figure 6). In addition, apoptotic cells were found in the ONL layer, suggestive of damages in the photoreceptor nuclei. No such staining was observed in the LDLR–/–ApoB100/100 control littermates. To evaluate the retinal structure, rhodopsin immunostaining was performed. Rhodopsin staining was reduced in the retinas of IGF-II/LDLR–/–ApoB100/100 mice, consistent with the decreased number of photoreceptor cells (Figure 6).


In the present study the ocular morphology of IGF-II/LDLR–/–ApoB100/100 mice, demonstrating a prediabetic state in a hypercholesterolemic background, was characterized. Compared to hyperlipidemic LDLR–/–ApoB100/100 controls, we found that IGF-II/LDLR–/–ApoB100/100 mice on a control or Western diet displayed altered retinal morphology and photoreceptor atrophy, suggesting the presence of retinal degeneration and a novel form of retinopathy.

Several factors could potentially contribute to the observed ocular changes. First, hyperglycemia is known to trigger a cascade of metabolic and biochemical changes in the retina long before any associated disease can be detected [21]. Moreover, it is associated with biochemical alterations and apoptosis of neuronal and vascular cells in the retina [22,23]. Many diabetic mouse models, such as leptin receptor-deficient db/db mice [24] and mice where hyperglycemia is induced by streptozocin [25] or galactose feeding [26], develop vascular and neural changes typical of early stages of DR. However, overexpression of IGF-II in the LDLR–/–ApoB100/100 background results in impaired glucose tolerance, insulin resistance, and moderately increased blood glucose levels [16], which together simulate more of a metabolic disorder or a prediabetic state rather than full-blown diabetes. Although the absence of profound hyperglycemia could contribute to the observed lack of typical diabetic vascular alterations in this model, it is not exclusionary since the development of vascular lesions does occur in type 2 diabetic patients who already have a moderate degree of hyperglycemia [27].

Second, disturbances in glucose metabolism in the LDLR–/–ApoB100/100 mice were caused by overexpression of IGF-II, and thus the possibility of direct effects of IGF-II on the eye should also be considered. In general, many growth factors have been associated with the ocular changes seen in diabetes and more specifically with the development of vascular lesions in DR. Indeed, growth factors have been needed to achieve the most advanced DR phenotypes in mice where severe hyperglycemia alone has not been enough to elicit profound DR [28]. One such example model is the Akimba mouse where transgenic upregulation of vascular endothelial growth factor (VEGF) in photoreceptors induces neovascular changes and characteristics of proliferative DR [29]. Also, transgenic mice with a robust overexpression of IGF-I in the retina display most of the alterations seen in human DR [30], while a similar model with a lower expression level of IGF-I does not develop any ocular abnormalities [31]. However, the role of IGF-II has been studied to a lesser extent. IGF-II is an important growth factor during embryonic development, but the levels decrease considerably after birth and are very low in adult rodents [32]. Despite the low systemic levels, IGF-II has been observed to be present in the retina of adult rats [33]. This was not noted in C57BL/6 or LDLR–/–ApoB100/100 control animals in the present study. However, IGF-II expression was observed in the retinal capillaries of the IGF-II transgenic mice. In these mice, the transgene expression is regulated by the rat insulin-I promoter (RIP-I), leading to expression mainly in pancreatic β-cells, while no expression in liver or muscle cells has been observed [19]. Nevertheless, it seems that the promoter is also active in the retina since the same RIP-I/β-globin expression vector [34] has been used in the generation of IGF-I transgenic mice with strong retinal expression of IGF-I and a profound DR phenotype [29]. In fact, biosynthesis of preproinsulin has been detected in various sites outside the pancreas, e.g., in the rat retina [35], which could explain the observed retinal expression of the IGF-II transgene in the present study.

Could increased IGF-II expression then underlie the observed changes in the retina? Increased ocular IGF-II levels have been observed in mice with oxygen-induced retinopathy [36,37]. In those studies IGF-II was stated to be important for photoreceptor cell survival and vessel growth [37], with its angiogenic properties being mediated through direct effects as well as indirectly through VEGF induction [36]. However, despite the increased expression of IGF-II in the retinal capillaries, the observed abnormalities in our study were the opposite from those stated previously in other models. Therefore, alternative explanations for the observed pathology should be considered.

Another possible factor driving the observed retinal abnormalities is dyslipidemia. This has been shown to contribute to the pathogenesis of different ocular diseases, and accumulation of lipids into the sub-RPE space has been observed in different hypercholesterolemic mouse models [11,15,38,39]. In the present study, the only common finding for both hyperlipidemic strains was the significantly decreased cell number in INL when compared to normolipidemic C57Bl/6J mice. This has also been observed in hypercholesterolemic ApoE-deficient mice, indicating some degree of degeneration of the inner retinal cell layers [40]. Therefore, it is possible that supraphysiological cholesterol levels have also induced such changes in the LDLR–/–ApoB100/100 background. However, since no other changes in the sub-RPE space typical to hyperlipidemia were encountered and since IGF-II transgenic mice presented significantly more intraretinal changes than the LDLR–/–ApoB100/100 mice with similar plasma lipid levels, it is unlikely that hyperlipidemia would be the major underlying factor of the observed changes in the IGF-II/LDLR–/–ApoB100/100 mice.

What about genetic factors? It is generally acknowledged that inbred mouse strains carry mutations that can have an effect on the ocular phenotype. For example, the retinal degeneration 1 mutation Pde6brd1 is present in many generally used inbred mouse strains and causes blindness when two copies of the mutated gene are present [41]. One of the strains carrying this mutation is SJL, which is also the strain used in the generation of the original IGF-II transgenic mouse [19]. Therefore, in theory, it is possible that the mutation would still be present in the studied animals. However, this is not presumable for two reasons. First, the IGF-I transgenic mice do not show any signs of retinal degeneration although they are in a pure SJL background [29]. Second, after crossbreeding with the LDLR–/–ApoB100/100 strain, the IGF-II/LDLR–/–ApoB100/100 mice have been backcrossed for over 10 years to LDLR–/–ApoB100/100 mice in the C57BL/6×129/SvJae background.

Since chronic inflammation is involved in the pathogenesis of DR [42,43] and since the aortic walls of IGF-II/LDLR–/–ApoB100/100 mice were found to present a more inflammatory phenotype compared to LDLR–/–ApoB100/100 mice in earlier studies [16,17], retinas were examined for signs of inflammation. However, the retinal expression of adhesion molecules ICAM-1 and VCAM-1 as well as caspase-1 was not increased in the IGF-II/LDLR–/–ApoB100/100 mice. Advanced glycation end products have also been suggested to induce retinal expression of IL-6 [44], which subsequently induces the expression of VEGF [45], the primary mediator of retinal neovascularization. Nevertheless, in the present study the expressions of either IL-6 or RAGE were not increased in the IGF-II/LDLR–/–ApoB100/100 mice, which is in line with the absence of angiogenic changes.

Increased activation of caspase-3 was seen in retinas of the IGF-II/LDLR–/–ApoB100/100 mice. The number of cells in the ONL, consisting mainly of photoreceptor cell nuclei, was significantly decreased in IGF-II/LDLR–/–ApoB100/100 mice compared to both LDLR–/–ApoB100/100 mice and C57Bl/6J control mice. Together with TUNEL-positive cells and reduced rhodopsin positivity, this is indicative of photoreceptor atrophy. During the prediabetic phase, anomalies might be developing due to changes in the circulation and insufficient oxygen supply in the retina [46,47]. Therefore, it has been suggested that the level of photoreceptor metabolism could play a role in the initiation and progression of DR [48,49]. Reduced retinal metabolism would decrease oxygen demand and thus ameliorate the hypoxia that triggers VEGF production and consequent neovascularization. Indeed, it has been observed both in humans and mice that conditions associated with photoreceptor degeneration, such as AMD and retinitis pigmentosa, are protective from reactive retinal neovascularization typical in DR [48,49]. In fact, caspase-3 activation is generally seen in animal models with either inherited or induced photoreceptor degeneration: the rd-1 mouse [50,51], rhodopsin mutant rat [52], chemically induced retinal degeneration [53], and photoreceptor degeneration following blue light exposure [54]. Hence, it is possible that excessive photoreceptor atrophy is also protective against diabetic microvascular changes in the IGF-II/LDLR–/–ApoB100/100 mice.

In conclusion, IGF-II/LDLR–/–ApoB100/100 mice displayed photoreceptor atrophy and abundant changes in retinal morphology. As a limitation to the study, only one time point was evaluated, and therefore conclusions about the temporal profile of the morphological changes cannot be drawn. Importantly, the observed changes were not characteristic of typical diabetic retinopathy but describe a novel form of retinopathy. Further studies assessing, e.g., the ocular ultrastructure and retinal function with electroretinography, are needed for elucidating the exact etiology of these pathological changes and for a complete ocular characterization of this animal model.


This study was supported by grants from Finnish Academy, Finnish Cultural Foundation of Northern Savo and the European Union (SUMMIT EUFP7 Consortium grant 115006).


  1. Wingard DL, Barrett-Connor EL, Scheidt-Nave C, McPhillips JB. Prevalence of cardiovascular and renal complications in older adults with normal or impaired glucose tolerance or NIDDM. A population-based study. Diabetes Care. 1993; 16:1022-5. [PMID: 8359095]
  2. WHO Study Group. The prevention of blindness. World Health Organ Tech Rep Ser. 1973; 518:1-18. [PMID: 4633470]
  3. Diabetes Control and Complications Trial. The absence of a glycemic threshold for the development of long-term complications: The perspective of the diabetes control and complications trial. Diabetes. 1996; 45:1289-98. [PMID: 8826962]
  4. UK Prospective Diabetes Study 6. Complications in newly diagnosed type 2 diabetic patients and their association with different clinical and biochemical risk factors. Diabetes Res. 1990; 13:1-11. [PMID: 2097090]
  5. Lyons TJ, Jenkins AJ, Zheng D, Lackland DT, McGee D, Garvey WT, Klein RL. Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/EDIC cohort. Invest Ophthalmol Vis Sci. 2004; 45:910-8. [PMID: 14985310]
  6. Klein R, Sharrett AR, Klein BEK, Moss SE, Folsom AR, Wong TY, Brancati FL, Hubbard LD, Couper D. The association of atherosclerosis, vascular risk factors, and retinopathy in adults with diabetes: The atherosclerosis risk in communities study. Ophthalmology. 2002; 109:1225-34. [PMID: 12093643]
  7. Klein R, Klein BE, Linton KL. Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology. 1992; 99:933-43. [PMID: 1630784]
  8. Holz FG, Sheraidah G, Pauleikhoff D, Bird AC. Analysis of lipid deposits extracted from human macular and peripheral Bruch's membrane. Arch Ophthalmol. 1994; 112:402-6. [PMID: 8129668]
  9. Pauleikhoff D, Harper CA, Marshall J, Bird AC. Aging changes in Bruch's membrane. A histochemical and morphologic study. Ophthalmology. 1990; 97:171-8. [PMID: 1691475]
  10. Seddon JM, Rosner B, Sperduto RD, Yannuzzi L, Haller JA, Blair NP, Willett W. Dietary fat and risk for advanced age-related macular degeneration. Arch Ophthalmol. 2001; 119:1191-9. [PMID: 11483088]
  11. Rudolf M, Winkler B, Aherrahou Z, Doehring LC, Kaczmarek P, Schmidt-Erfurth U. Increased expression of vascular endothelial growth factor associated with accumulation of lipids in Bruch's membrane of LDL receptor knockout mice. Br J Ophthalmol. 2005; 89:1627-30. [PMID: 16299144]
  12. Curcio CA, Millican CL. Basal linear deposit and large drusen are specific for early age-related maculopathy. Arch Ophthalmol. 1999; 117:329-39. [PMID: 10088810]
  13. Malek G, Li C, Guidry C, Medeiros NE, Curcio CA. Apolipoprotein B in cholesterol-containing drusen and basal deposits of human eyes with age-related maculopathy. Am J Pathol. 2003; 162:413-25. [PMID: 12547700]
  14. Espinosa-Heidmann DG, Sall J, Hernandez EP, Cousins SW. Basal laminar deposit formation in APO B100 transgenic mice: Complex interactions between dietary fat, blue light, and vitamin E. Invest Ophthalmol Vis Sci. 2004; 45:260-6. [PMID: 14691182]
  15. Bretillon L, Acar N, Seeliger MW, Santos M, Maire MA, Juaneda P, Martine L, Gregoire S, Joffre C, Bron AM, Creuzot-Garcher C. ApoB100,LDLR−/− mice exhibit reduced electroretinographic response and cholesteryl esters deposits in the retina. Invest Ophthalmol Vis Sci. 2008; 49:1307-14. [PMID: 18385042]
  16. Heinonen SE, Leppanen P, Kholova I, Lumivuori H, Hakkinen S, Bosch F, Laakso M, Yla-Herttuala S. Increased atherosclerotic lesion calcification in a novel mouse model combining insulin resistance, hyperglycemia, and hypercholesterolemia. Circ Res. 2007; 101:1058-67. [PMID: 17872464]
  17. Heinonen SE, Merentie M, Hedman M, Mäkinen PI, Loponen E, Kholová I, Bosch F, Laakso M, Ylä-Herttuala S. Left ventricular dysfunction with reduced functional cardiac reserve in diabetic and non-diabetic LDL-receptor deficient apolipoprotein B100-only mice. Cardiovasc Diabetol. 2011; 10:59 [PMID: 21718508]
  18. Véniant MM, Zlot CH, Walzem RL, Pierotti V, Driscoll R, Dichek D, Herz J, Young SG. Lipoprotein clearance mechanisms in LDL receptor-deficient “apo-B48-only” and “apo-B100-only” mice. J Clin Invest. 1998; 102:1559-68. [PMID: 9788969]
  19. Devedjian JC, George M, Casellas A, Pujol A, Visa J, Pelegrin M, Gros L, Bosch F. Transgenic mice overexpressing insulin-like growth factor-II in beta cells develop type 2 diabetes. J Clin Invest. 2000; 105:731-40. [PMID: 10727441]
  20. Leppänen P, Koota S, Kholova I, Koponen J, Fieber C, Eriksson U, Alitalo K, Yla-Herttuala S. Gene transfers of vascular endothelial growth factor-A, vascular endothelial growth factor-B, vascular endothelial growth factor-C, and vascular endothelial growth factor-D have no effects on atherosclerosis in hypercholesterolemic low-density lipoprotein-receptor/apolipoprotein B48-deficient mice. Circulation. 2005; 112:1347-52. [PMID: 16129816]
  21. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001; 414:813-20. [PMID: 11742414]
  22. Gardner TW, Antonetti DA, Barber AJ, LaNoue KF, Levison SW. Diabetic retinopathy: More than meets the eye. Surv Ophthalmol. 2002; 47Suppl 2:S253-62. [PMID: 12507627]
  23. Mizutani M, Kern TS, Lorenzi M. Accelerated death of retinal microvascular cells in human and experimental diabetic retinopathy. J Clin Invest. 1996; 97:2883-90. [PMID: 8675702]
  24. Cheung AK, Fung MK, Lo AC, Lam TT, So KF, Chung SS, Chung SK. Aldose reductase deficiency prevents diabetes-induced blood-retinal barrier breakdown, apoptosis, and glial reactivation in the retina of db/db mice. Diabetes. 2005; 54:3119-25. [PMID: 16249434]
  25. Feit-Leichman RA, Kinouchi R, Takeda M, Fan Z, Mohr S, Kern TS, Chen DF. Vascular damage in a mouse model of diabetic retinopathy: Relation to neuronal and glial changes. Invest Ophthalmol Vis Sci. 2005; 46:4281-7. [PMID: 16249509]
  26. Kern TS, Engerman RL. A mouse model of diabetic retinopathy. Arch Ophthalmol. 1996; 114:986-90. [PMID: 8694735]
  27. Klein R, Klein BE, Moss SE. Epidemiology of proliferative diabetic retinopathy. Diabetes Care. 1992; 15:1875-91. [PMID: 1464243]
  28. Robinson R, Barathi VA, Chaurasia SS, Wong TY, Kern TS. Update on animal models of diabetic retinopathy: From molecular approaches to mice and higher mammals. Dis Model Mech. 2012; 5:444-56. [PMID: 22730475]
  29. Rakoczy EP, Ali Rahman IS, Binz N, Li CR, Vagaja NN, de Pinho M, Lai CM. Characterization of a mouse model of hyperglycemia and retinal neovascularization. Am J Pathol. 2010; 177:2659-70. [PMID: 20829433]
  30. Ruberte J, Ayuso E, Navarro M, Carretero A, Nacher V, Haurigot V, George M, Llombart C, Casellas A, Costa C, Bosch A, Bosch F. Increased ocular levels of IGF-1 in transgenic mice lead to diabetes-like eye disease. J Clin Invest. 2004; 113:1149-57. [PMID: 15085194]
  31. Hu W, Wang W, Gao H, Zhong J, Yao W, Lee WH, Ye P, Qiao X. Lack of spontaneous ocular neovascularization and attenuated laser-induced choroidal neovascularization in IGF-I overexpression transgenic mice. Vision Res. 2007; 47:776-82. [PMID: 17275062]
  32. Chao W, D’Amore PA. IGF2: Epigenetic regulation and role in development and disease. Cytokine Growth F R. 2008; 19:111-20. [PMID: 18308616]
  33. Danias J, Stylianopoulou F. Expression of IGF-I and IGF-II genes in the adult rat eye. Curr Eye Res. 1990; 9:379-86. [PMID: 1692782]
  34. George M, Ayuso E, Casellas A, Costa C, Devedjian JC, Bosch F. Beta cell expression of IGF-I leads to recovery from type 1 diabetes. J Clin Invest. 2002; 109:1153-63. [PMID: 11994404]
  35. Budd GC, Pansky B, Glatzer L. Preproinsulin mRNA in the rat eye. Invest Ophthalmol Vis Sci. 1993; 34:463-9. [PMID: 8440600]
  36. Kim JH, Park SW, Yu YS, Kim K, Kim JH. Hypoxia-induced insulin-like growth factor II contributes to retinal vascularization in ocular development. Biochimie. 2012; 94:734-40. [PMID: 22120545]
  37. Lofqvist C, Willett KL, Aspegren O, Smith ACH, Aderman CM, Connor KM, Chen J, Hellstrom A, Smith LEH. Quantification and localization of the IGF/Insulin system expression in retinal blood vessels and neurons during oxygen-induced retinopathy in mice. Invest Ophthalmol Vis Sci. 2009; 50:1831-7. [PMID: 18997086]
  38. Kliffen M, Lutgens E, Daemen MJ, de Muinck ED, Mooy CM, de Jong PT. The APO(*)E3-Leiden mouse as an animal model for basal laminar deposit. Br J Ophthalmol. 2000; 84:1415-9. [PMID: 11090485]
  39. Dithmar S, Curcio CA, Le NA, Brown S, Grossniklaus HE. Ultrastructural changes in Bruch's membrane of apolipoprotein E-deficient mice. Invest Ophthalmol Vis Sci. 2000; 41:2035-42. [PMID: 10892840]
  40. Ong JM, Zorapapel NC, Rich KA, Wagstaff RE, Lambert RW, Rosenberg SE, Moghaddas F, Pirouzmanesh A, Aoki AM, Kenney MC. Effects of cholesterol and apolipoprotein E on retinal abnormalities in ApoE-deficient mice. Invest Ophthalmol Vis Sci. 2001; 42:1891-900. [PMID: 11431458]
  41. Genetic background effects: Can your mice see? JAX notes. . 2002;
  42. Tang J, Kern TS. Inflammation in diabetic retinopathy. Prog Retin Eye Res. 2011; 30:343-58. [PMID: 21635964]
  43. Brucklacher RM, Patel KM, VanGuilder HD, Bixler GV, Barber AJ, Antonetti DA, Lin CM, LaNoue KF, Gardner TW, Bronson SK, Freeman WM. Whole genome assessment of the retinal response to diabetes reveals a progressive neurovascular inflammatory response. BMC Med Genomics. 2008; 1:26 [PMID: 18554398]
  44. Nakamura N, Hasegawa G, Obayashi H, Yamazaki M, Ogata M, Nakano K, Yoshikawa T, Watanabe A, Kinoshita S, Fujinami A, Ohta M, Imamura Y, Ikeda T. Increased concentration of pentosidine, an advanced glycation end product, and interleukin-6 in the vitreous of patients with proliferative diabetic retinopathy. Diabetes Res Clin Pract. 2003; 61:93-101. [PMID: 12951277]
  45. Cohen T, Nahari D, Cerem LW, Neufeld G, Levi B. Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem. 1996; 271:736-41. [PMID: 8557680]
  46. Fortune B, Schneck ME, Adams AJ. Multifocal electroretinogram delays reveal local retinal dysfunction in early diabetic retinopathy. Invest Ophthalmol Vis Sci. 1999; 40:2638-51. [PMID: 10509661]
  47. Patel V, Rassam S, Newsom R, Wiek J, Kohner E. Retinal blood flow in diabetic retinopathy. BMJ. 1992; 305:678-83. [PMID: 1393111]
  48. Arden GB. The absence of diabetic retinopathy in patients with retinitis pigmentosa: Implications for pathophysiology and possible treatment. Br J Ophthalmol. 2001; 85:366-70. [PMID: 11222350]
  49. Lahdenranta J, Pasqualini R, Schlingemann RO, Hagedorn M, Stallcup WB, Bucana CD, Sidman RL, Arap W. An anti-angiogenic state in mice and humans with retinal photoreceptor cell degeneration. Proc Natl Acad Sci USA. 2001; 98:10368-73. [PMID: 11526242]
  50. Jomary C, Neal MJ, Jones SE. Characterization of cell death pathways in murine retinal neurodegeneration implicates cytochrome c release, caspase activation, and bid cleavage. Mol Cell Neurosci. 2001; 18:335-46. [PMID: 11640892]
  51. Kim DH, Kim JA, Choi JS, Joo CK. Activation of caspase-3 during degeneration of the outer nuclear layer in the rd mouse retina. Ophthalmic Res. 2002; 34:150-7. [PMID: 12097798]
  52. Liu C, Li Y, Peng M, Laties AM, Wen R. Activation of caspase-3 in the retina of transgenic rats with the rhodopsin mutation S334ter during photoreceptor degeneration. J Neurosci. 1999; 19:4778-85. [PMID: 10366612]
  53. Yoshizawa K, Yang J, Senzaki H, Uemura Y, Kiyozuka Y, Shikata N, Oishi Y, Miki H, Tsubura A. Caspase-3 inhibitor rescues N -methyl- N -nitrosourea-induced retinal degeneration in Sprague-Dawley rats. Exp Eye Res. 2000; 71:629-35. [PMID: 11095915]
  54. Wu J, Gorman A, Zhou X, Sandra C, Chen E. Involvement of caspase-3 in photoreceptor cell apoptosis induced by in vivo blue light exposure. Invest Ophthalmol Vis Sci. 2002; 43:3349-54. [PMID: 12356844]